Three-Dimensional Lung Tumor Microenvironment Modulates Therapeutic Compound Responsiveness In Vitro – Implication for Drug Development
暂无分享,去创建一个
Kjell Johnson | Jose Pardinas | J. Pardinas | J. Ekert | Stephen Jarantow | B. Strake | D. Colter | Jason E. Ekert | Kjell Johnson | Stephen W. Jarantow | R. Perkinson | Brandy Strake | Robert Perkinson | David C. Colter | J. Pardinas | Brandy Strake
[1] Soo-Jeong Choi,et al. Anti-tumor activity of noble indirubin derivatives in human solid tumor models In Vitro , 2009, Archives of pharmacal research.
[2] Andreas Krieg,et al. Impact of the 3D Microenvironment on Phenotype, Gene Expression, and EGFR Inhibition of Colorectal Cancer Cell Lines , 2013, PloS one.
[3] C. Verbeke,et al. 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing , 2013, BMC Cancer.
[4] Kristiina Vuori,et al. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures , 2007, Molecular Cancer Therapeutics.
[5] H. Poulsen,et al. Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies , 2012, BioDrugs.
[6] P. Friedl. Prespecification and plasticity: shifting mechanisms of cell migration. , 2004, Current opinion in cell biology.
[7] M. Willingham,et al. A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. , 2003, Cancer research.
[8] C. V. van Blitterswijk,et al. Layer-by-layer tissue microfabrication supports cell proliferation in vitro and in vivo. , 2012, Tissue engineering. Part C, Methods.
[9] G. Watanabe,et al. Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors , 2009, Clinical Cancer Research.
[10] C. Croce,et al. Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2 , 2013, Proceedings of the National Academy of Sciences.
[11] F. Siannis,et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. , 2008, The Lancet. Oncology.
[12] L. Kunz-Schughart,et al. Multicellular tumor spheroids: an underestimated tool is catching up again. , 2010, Journal of biotechnology.
[13] Walter Klepetko,et al. Cell migration or cytokinesis and proliferation?--revisiting the "go or grow" hypothesis in cancer cells in vitro. , 2013, Experimental cell research.
[14] W. Hait,et al. Anticancer drug development: the grand challenges , 2010, Nature Reviews Drug Discovery.
[15] Juergen Friedrich,et al. Spheroid-based drug screen: considerations and practical approach , 2009, Nature Protocols.
[16] Shuichi Takayama,et al. High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. , 2011, The Analyst.
[17] Mitchell Ho,et al. Rapid Generation of In Vitro Multicellular Spheroids for the Study of Monoclonal Antibody Therapy , 2011, Journal of Cancer.
[18] Joseph A DiMasi,et al. Economics of new oncology drug development. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Benjamin M Wu,et al. Incorporation of multicellular spheroids into 3‐D polymeric scaffolds provides an improved tumor model for screening anticancer drugs , 2010, Cancer science.
[20] T. Mitsudomi,et al. Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer , 2012, Molecular Cancer Therapeutics.
[21] B. Al-Lazikani,et al. Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance , 2012, Clinical pharmacology and therapeutics.
[22] C. Klein,et al. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity , 2013, Oncogene.
[23] J. Christensen,et al. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. , 2005, Cancer letters.
[24] S. Marlovits,et al. Impact of 3D-culture on the expression of differentiation markers and hormone receptors in growth plate chondrocytes as compared to articular chondrocytes. , 2009, International journal of molecular medicine.
[25] X. Paoletti,et al. Development of anti-cancer drugs. , 2010, Discovery medicine.
[26] E. Shimizu,et al. Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity , 2012, Cancer biology & therapy.
[27] E. Brown,et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. , 2005, Cancer research.
[28] S. Eccles,et al. Tumor spheroid-based migration assays for evaluation of therapeutic agents. , 2013, Methods in molecular biology.
[29] G. V. Vande Woude,et al. MET: a critical player in tumorigenesis and therapeutic target. , 2013, Cold Spring Harbor perspectives in biology.
[30] I. Kasman,et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. , 2007, Cancer research.
[31] P. Workman,et al. Resisting targeted therapy: fifty ways to leave your EGFR. , 2011, Cancer Cell.
[32] Y. Sekido,et al. Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer , 2009, Clinical Cancer Research.
[33] R. Mattingly,et al. Three-Dimensional Overlay Culture Models of Human Breast Cancer Reveal a Critical Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibitors , 2010, Journal of Pharmacology and Experimental Therapeutics.
[34] Olga Ilina,et al. Mechanisms of collective cell migration at a glance , 2009, Journal of Cell Science.
[35] J. Beck,et al. KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib. , 2011, Oncology reports.
[36] L. Cazin,et al. Hyaluronan hydrogel: an appropriate three-dimensional model for evaluation of anticancer drug sensitivity. , 2008, Acta Biomaterialia.
[37] L. O’Driscoll,et al. Three-dimensional cell culture: the missing link in drug discovery. , 2013, Drug discovery today.
[38] M. Westphal,et al. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ. , 2013, Neuro-oncology.
[39] E. Giovannetti,et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] R. Salgia,et al. Role of MetMAb (OA-5D5) in c-MET active lung malignancies , 2011, Expert opinion on biological therapy.
[41] J. Hainsworth,et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] D. Stolz,et al. Cross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells* , 2000, The Journal of Biological Chemistry.
[43] C. Ries,et al. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab , 2009, Oncogene.
[44] H. Uramoto,et al. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. , 2011, Lung cancer.
[45] L. Windus,et al. Chemokine receptor expression on integrin-mediated stellate projections of prostate cancer cells in 3D culture. , 2013, Cytokine.
[46] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[47] N. Hiraoka,et al. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma , 2011, British Journal of Cancer.
[48] Y. Yatabe,et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. , 2008, Cancer research.
[49] Ravi Salgia,et al. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer , 2008, Journal of carcinogenesis.
[50] Aimin Zhou,et al. Development, validation and pilot screening of an in vitro multi-cellular three-dimensional cancer spheroid assay for anti-cancer drug testing. , 2013, Bioorganic & medicinal chemistry.
[51] Hai Hu,et al. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice , 2011, Breast Cancer Research.
[52] I. Kola,et al. The State of Innovation in Drug Development , 2008, Clinical pharmacology and therapeutics.
[53] Hiroaki Sakurai,et al. Transient Suppression of Ligand-mediated Activation of Epidermal Growth Factor Receptor by Tumor Necrosis Factor-α through the TAK1-p38 Signaling Pathway* , 2007, Journal of Biological Chemistry.
[54] L. Windus,et al. In vivo biomarker expression patterns are preserved in 3D cultures of Prostate Cancer. , 2012, Experimental cell research.
[55] Deborah S. Barkauskas,et al. Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer , 2008, British Journal of Cancer.
[56] Shinji Takeuchi,et al. Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells , 2012, Clinical Cancer Research.
[57] Tobias Schmelzle,et al. Engineering tumors with 3D scaffolds , 2007, Nature Methods.
[58] R. Sun,et al. HGF stimulates proliferation through the HGF/c-Met pathway in nasopharyngeal carcinoma cells. , 2012, Oncology letters.
[59] M. Westphal,et al. A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo , 2006, Clinical Cancer Research.
[60] D. Barnes. Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture , 1982, The Journal of cell biology.
[61] F. Hirsch,et al. Hepatocyte growth factor expression in EGFR-mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] I. Okamoto,et al. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification , 2011, British Journal of Cancer.
[63] S. Yano,et al. Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[64] Luc Stoppini,et al. OrganDots – an organotypic 3D tissue culture platform for drug development , 2012, Expert opinion on drug discovery.
[65] M. Meyerson,et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. , 2009, Cancer research.
[66] M. Park,et al. From Tpr-Met to Met, tumorigenesis and tubes , 2007, Oncogene.
[67] J. Siegfried,et al. Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells , 2011, Clinical Cancer Research.
[68] N. Steimberg,et al. Modelling tissues in 3D: the next future of pharmaco-toxicology and food research? , 2009, Genes & Nutrition.
[69] Maria Vinci,et al. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation , 2012, BMC Biology.